Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
Executive Summary
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.
You may also be interested in...
PacBio Unveils TRGT, A Tool For Characterizing Rare Disease
PacBio's TRGT can sequence broader sections of DNA, giving scientists and clinicians better odds of spotting repeated sections of DNA linked to disease.
Minute Insight: Maestro Cues The Music With CE Mark For Moon Surgical
The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.
Minute Insight: 15,000 Surgeries And More Funding For CMR Surgical
The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.